Immunonutrition Supplementation for Improved Burn Wound Healing in Older Adults

Sponsor
University of Wisconsin, Madison (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04725071
Collaborator
(none)
20
1
2
7.1
2.8

Study Details

Study Description

Brief Summary

This pilot study aims to assess the feasibility of providing immunonutrition supplementation to older burn patients (age 65 and older) and its impact on burn wound healing. Supplements containing arginine and omega 3 fatty acids have been shown to have beneficial effects on healing in other types of wounds but data within the burn population remains limited. 20 participants will be randomized into two arms, immunonutrition or conventional supplement and can expect to be on study for 3 months.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Impact Advanced Recovery
  • Dietary Supplement: Boost High Protein
N/A

Detailed Description

Studies performed previously in burn patients have had mixed patient cohorts with small sample sizes and these have failed to show any large improvements in wound healing. However, in older populations the investigators suspect that immunonutrition supplements may have a larger benefit to these patients as they often present with malnutrition and are more likely to struggle with delayed wound healing. In this pilot study, the investigators look to assess the impact of immunonutrition supplements the burn wound healing of adults over the age of 65 years with 5-15% total burn surface area (TBSA) partial thickness and full thickness burn injuries.

The primary outcome objective of the study will be time to complete wound closure. The secondary objectives include need for surgical grafting, length of inpatient stay, and infections including pneumonia, urinary tract infections, wound infections, and blood stream infections.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Immunonutrition Supplementation for Improved Burn Wound Healing in Older Adults
Actual Study Start Date :
Jul 1, 2022
Anticipated Primary Completion Date :
Feb 1, 2023
Anticipated Study Completion Date :
Feb 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Immunonutrition

Participants will consume a 6oz immunonutrition drink 2 times daily for 7 days and then once a day for remaining hospital stay.

Dietary Supplement: Impact Advanced Recovery
L-arginine and omega-3 rich supplement

Active Comparator: Conventional Supplement

Participants will consume a 6oz conventional supplement drink 3 times daily for 7 days and then once a day for remaining hospital stay.

Dietary Supplement: Boost High Protein
conventional supplement

Outcome Measures

Primary Outcome Measures

  1. Time to Complete Wound Closure [up to 3 months]

Secondary Outcome Measures

  1. Incidence of Surgical Grafting [up to 3 months]

  2. Length of Inpatient Stay [up to 3 months]

  3. Incidence of Infections [up to 3 months]

    Infectious complications include pneumonia, urinary tract infection, wound infection, and blood stream infection.

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subject has partial of full thickness thermal injury of 5-15% of total body surface area (TBSA)

  • Subject has an inpatient admission for their burn

  • Subject or authorized decision maker understands the study procedures and can provide informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator

Exclusion Criteria:
  • Subject with inhalation injury and/or intubation

  • Subject receiving immunosuppressive medications including chronic steroids, immune modulating medications, and chemotherapy prior to admission

  • Subject with pre-existing severe chronic liver disease or end stage renal disease

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Wisconsin Madison Wisconsin United States 53792

Sponsors and Collaborators

  • University of Wisconsin, Madison

Investigators

  • Principal Investigator: Rebecca A Busch, MD, FACS, University of Wisconsin, Madison

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT04725071
Other Study ID Numbers:
  • 2020-1692
  • A539714
  • SMPH/SURGERY/TRAUMA
  • Protocol Version 1/14/2021
First Posted:
Jan 26, 2021
Last Update Posted:
Jul 5, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Wisconsin, Madison
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 5, 2022